文献速递多重用药老年慢病共病管理安宁疗护

临终关怀入院时抗血栓治疗处方 prevalence 及影响因素

Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission.
PubMed 文献 · J Am Geriatr Soc · 2025-10-16

本研究基于美国大型临终关怀机构2017-2019年电子健康记录,对54,643例成年死亡患者进行横断面分析,发现20.8%在入院时至少有一种抗血栓药物处方。功能状态较好(PPS较高)及在非住院临终关怀场所接受照护的患者更可能获得抗血栓处方。

要点

  • 临终关怀入院时20.8%患者有抗血栓处方,抗血小板药占15.7%,直接口服抗凝药占3.7%。
  • PPS评分20%-30%、40%-50%、60%-100%者较PPS<20%者抗血栓处方aOR分别为9.38、15.69、15.67。
  • 辅助生活机构、养老院或居家照护者较住院临终关怀场所更可能获抗血栓处方(aOR 4.34、4.02、4.08)。

核心结论

  • 临终关怀入院时抗血栓治疗较普遍,且与患者预后较好及非住院临终关怀照护场所相关。

研究设计与样本

  • 横断面研究,使用美国大型营利性临终关怀连锁机构2017年1月1日至2019年12月31日死亡的成年(≥18岁)患者电子健康记录数据。

主要发现

  • 54,643例临终关怀死亡患者中,平均年龄79.7岁(SD 13.2),44.6%为男性,57.0%为白人。
  • 临终关怀住院时间中位数9天(IQR 3-40),18,531例(33.9%)PPS评分为30%。
  • 11,360例(20.8%)在临终关怀入院时至少有一种抗血栓处方;最常用类别为抗血小板药(15.7%)和直接口服抗凝药(3.7%)。
  • 与PPS<20%者相比,PPS 20%-30%(aOR 9.38,95%CI 8.03-10.95)、40%-50%(aOR 15.69,95%CI 13.38-18.40)、60%-100%(aOR 15.67,95%CI 12.41-19.79)者更可能接受抗血栓处方。
  • 与住院临终关怀场所相比,辅助生活机构(aOR 4.34,95%CI 3.86-4.87)、养老院(aOR 4.02,95%CI 3.62-4.47)或居家(aOR 4.08,95%CI 3.74-4.45)照护者更可能接受抗血栓处方。

临床怎么用

  • 对临终关怀入院患者应评估抗血栓处方,尤其关注功能状态较好及非住院照护场所的患者。
  • 需进一步研究优化临终关怀中的抗血栓处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known regarding antithrombotic prescribing in U.S. hospice patients. We quantified the prevalence and predictors of receiving an antithrombotic prescription on hospice admission. METHODS: This was a cross-sectional study using electronic health record data from adult (age ≥ 18 years) decedents of a large, for-profit hospice chain who died between January 1, 2017, and December 31, 2019. Our primary outcome was having a prescription for antithrombotic (anticoagulant or antiplatelet) therapy on hospice admission. We used multivariable logistic regression to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULTS: Among 54,643 hospice decedents, the mean age was 79.7 (standard deviation (SD) 13.2) years, 44.6% were male, and 57.0% were White. The median hospice length of stay was 9 (interquartile range 3-40) days, and 18,531 patients (33.9%) had a Palliative Performance Scale (PPS) score of 30%. Overall, 11,360 patients (20.8%) had at least one antithrombotic prescription on hospice admission. The most frequently prescribed antithrombotic classes were antiplatelets (15.7%) and direct oral anticoagulants (3.7%). Patients with PPS scores of 20%-30% (adjusted OR (aOR) 9.38, 95% CI 8.03-10.95), 40%-50% (aOR 15.69, 95% CI 13.38-18.40), and 60%-100% (aOR 15.67, 95% CI 12.41-19.79) were significantly more likely to receive an antithrombotic prescription compared to patients with a PPS score < 20%. Additionally, patients receiving care in an assisted living facility (aOR 4.34, 95% CI 3.86-4.87), nursing home (aOR 4.02, 95% CI 3.62-4.47), or at home (aOR 4.08, 95% CI 3.74-4.45) were more likely to receive an antithrombotic prescription compared to patients receiving care in an inpatient hospice setting. CONCLUSIONS: Antithrombotic therapy was prevalent on hospice admission and most associated with better patient prognosis and non-inpatient hospice care locations. More research is needed to optimize antithrombotic prescribing in hospice care.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Short EK, Duong PY, Tjia J, et al. Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission. J Am Geriatr Soc. 2025. PMID: 41103072. doi:10.1111/jgs.70170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。